Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the ileum.
Biomarker and diagnostic research for ileal neuroendocrine tumor, well differentiated, low or intermediate grade has been reported in the published literature.
No clinical trials have been registered for ileal neuroendocrine tumor, well differentiated, low or intermediate grade.
211 publications have been identified in PubMed for ileal neuroendocrine tumor, well differentiated, low or intermediate grade. Kisho has analyzed 79 by research type. Research spans Review / Meta-Analysis (43%), Clinical Trial Publication (19%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 34 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:39 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Clinical study results | 15 | 19% |
Laboratory research | 11 | 14% |
Testing and diagnosis research | 9 | 11% |
Disease patterns and progression | 9 | 11% |
Patient case studies | 1 | 1% |
Hou G (2026). [PMID: 41134321](https://pubmed.ncbi.nlm.nih.gov/41134321/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]
Hercent A (2026). [PMID: 41416936](https://pubmed.ncbi.nlm.nih.gov/41416936/). *J Pathol*. [Basic Science / Preclinical]
Cella L (2026). [PMID: 42041162](https://pubmed.ncbi.nlm.nih.gov/42041162/). *Future Oncol*. [Review / Meta-Analysis]
Nilsson P (2026). [PMID: 41655576](https://pubmed.ncbi.nlm.nih.gov/41655576/). *Lancet Oncol*. [Clinical Trial Publication]
Su J (2026). [PMID: 41653198](https://pubmed.ncbi.nlm.nih.gov/41653198/). *Cancer Immunol Immunother*. [Review / Meta-Analysis]
van den Heerik ASVM (2026). [PMID: 41449145](https://pubmed.ncbi.nlm.nih.gov/41449145/). *Lancet Oncol*. [Clinical Trial Publication]
Cameron MA (2026). [PMID: 42106179](https://pubmed.ncbi.nlm.nih.gov/42106179/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Henderson RH (2026). [PMID: 41806873](https://pubmed.ncbi.nlm.nih.gov/41806873/). *Radiother Oncol*. [Clinical Trial Publication]
Virata MC (2026). [PMID: 41903203](https://pubmed.ncbi.nlm.nih.gov/41903203/). *Neuro Oncol*. [Basic Science / Preclinical]
Leung WK (2026). [PMID: 41057234](https://pubmed.ncbi.nlm.nih.gov/41057234/). *Gut*. [Review / Meta-Analysis]